WO2001081581A3 - Compositions et procedes pour la therapie et le diagnostic de l'acne vulgaire - Google Patents

Compositions et procedes pour la therapie et le diagnostic de l'acne vulgaire Download PDF

Info

Publication number
WO2001081581A3
WO2001081581A3 PCT/US2001/012865 US0112865W WO0181581A3 WO 2001081581 A3 WO2001081581 A3 WO 2001081581A3 US 0112865 W US0112865 W US 0112865W WO 0181581 A3 WO0181581 A3 WO 0181581A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
diagnosis
therapy
methods
acne vulgaris
Prior art date
Application number
PCT/US2001/012865
Other languages
English (en)
Other versions
WO2001081581A9 (fr
WO2001081581A2 (fr
Inventor
Yasir A W Skeiky
David H Persing
Jennifer L Mitcham
Siqing Steven Wang
Ajay Bhatia
Maisonneuve Jean-Francois L
Yanni Zhang
Shyian Jen
Darrick Carter
Original Assignee
Corixa Corp
Yasir A W Skeiky
David H Persing
Jennifer L Mitcham
Siqing Steven Wang
Ajay Bhatia
Maisonneuve Jean Francois L
Yanni Zhang
Shyian Jen
Darrick Carter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp, Yasir A W Skeiky, David H Persing, Jennifer L Mitcham, Siqing Steven Wang, Ajay Bhatia, Maisonneuve Jean Francois L, Yanni Zhang, Shyian Jen, Darrick Carter filed Critical Corixa Corp
Priority to EP01928693A priority Critical patent/EP1278854A2/fr
Priority to AU2001255524A priority patent/AU2001255524A1/en
Priority to CA002407352A priority patent/CA2407352A1/fr
Priority to JP2001578652A priority patent/JP2004520803A/ja
Publication of WO2001081581A2 publication Critical patent/WO2001081581A2/fr
Publication of WO2001081581A3 publication Critical patent/WO2001081581A3/fr
Publication of WO2001081581A9 publication Critical patent/WO2001081581A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne les compositions et les procédés pour la thérapie et le diagnostic de l'acné vulgaire et d'autres états apparentés. Les compositions peuvent comprendre une ou plusieurs protéines de Propionibacterium acnes, des fractions immunogènes de celles-ci, ou des polynucléotides qui codent de telles fractions. Selon une variante, une composition thérapeutique peut comprendre un anticorps qui fixe une protéine de Propionibacterium acnes, une cellule présentant un antigène qui exprime une protéine de Propionibacterium acnes, ou une cellule T qui agit spécifiquement sur les cellules exprimant une telle protéine. De telles compositions peuvent être utilisées, par exemple, pour la prévention et/ou le traitement de l'acné.
PCT/US2001/012865 2000-04-21 2001-04-20 Compositions et procedes pour la therapie et le diagnostic de l'acne vulgaire WO2001081581A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01928693A EP1278854A2 (fr) 2000-04-21 2001-04-20 Compositions et procedes pour la therapie et le diagnostic de l'acne vulgaire
AU2001255524A AU2001255524A1 (en) 2000-04-21 2001-04-20 Compositions and methods for the therapy and diagnosis of acne vulgaris
CA002407352A CA2407352A1 (fr) 2000-04-21 2001-04-20 Compositions et procedes pour la therapie et le diagnostic de l'acne vulgaire
JP2001578652A JP2004520803A (ja) 2000-04-21 2001-04-20 尋常性挫瘡の治療および診断のための組成物および方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US19904700P 2000-04-21 2000-04-21
US60/199,047 2000-04-21
US20884100P 2000-06-02 2000-06-02
US60/208,841 2000-06-02
US21674700P 2000-07-07 2000-07-07
US60/216,747 2000-07-07

Publications (3)

Publication Number Publication Date
WO2001081581A2 WO2001081581A2 (fr) 2001-11-01
WO2001081581A3 true WO2001081581A3 (fr) 2002-03-14
WO2001081581A9 WO2001081581A9 (fr) 2003-01-03

Family

ID=27393973

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/012865 WO2001081581A2 (fr) 2000-04-21 2001-04-20 Compositions et procedes pour la therapie et le diagnostic de l'acne vulgaire

Country Status (5)

Country Link
EP (1) EP1278854A2 (fr)
JP (1) JP2004520803A (fr)
AU (1) AU2001255524A1 (fr)
CA (1) CA2407352A1 (fr)
WO (1) WO2001081581A2 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2270030E (pt) 2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
US20020086837A1 (en) * 2000-12-21 2002-07-04 Jack Gauldie Acne vaccine
WO2002088175A1 (fr) * 2001-04-24 2002-11-07 Otsuka Pharmaceutical Co., Ltd. Peptide de liaison a des anticorps de la maladie de crohn et methode d'examen de ladite maladie
WO2003040172A2 (fr) * 2001-11-09 2003-05-15 Aegera Therapeutics, Inc. Procedes et reactifs destines aux tamis par interaction peptides-bir
WO2003059943A2 (fr) * 2002-01-18 2003-07-24 Karo Bio Ab Peptides specifiques a la conformation, de liaison de la proteine kinase, procedes et produits associes
IL165364A0 (en) * 2002-05-28 2006-01-15 Omrix Biopharmaceuticals Inc Method for obtaining anti-idiotype antibodies
US7432061B2 (en) * 2002-05-31 2008-10-07 Biozyme, Inc. Assays for measuring matrix metalloproteinase activities
DE10232776A1 (de) * 2002-07-18 2004-04-08 Henkel Kgaa Oligonukleotide zum Nachweis von Mikroorganismen
EP1576004A2 (fr) * 2002-12-23 2005-09-21 VIB vzw Proteine immunomodulatrice derivee des trypanosomes et ses utilisations
TWI262192B (en) * 2003-07-01 2006-09-21 Univ Nat Taiwan Labeling peptide for nasopharyngeal carcinoma (NPC) cells
US7723474B2 (en) * 2003-10-21 2010-05-25 The Regents Of The University Of California Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
WO2005047313A1 (fr) * 2003-11-14 2005-05-26 Peptide Door Co., Ltd. Peptide ou proteine apte a fixer le lipide a et le lps, adn codant ledit peptide ou ladite proteine et utilisation dudit peptide ou de ladite proteine, adsorbant de lps ou agent de neutralisation de poison de lps
AU2005221729B2 (en) * 2004-03-15 2009-09-24 Tissugen Pty Ltd Infectious aetiology of prostatic disease and methods to identify causative agents
CA2559390A1 (fr) * 2004-03-15 2005-09-22 Tissugen Pty Ltd Etiologie infectieuse de maladie prostatique et procede d'identification d'agents etiologiques
GB0409748D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
DE602004026284D1 (de) * 2004-07-01 2010-05-12 Biomay Ag Hausstaubmilbenallergen
US7501486B2 (en) 2004-09-07 2009-03-10 Burnham Institute For Medical Research Peptides that selectively home to heart vasculature and related conjugates and methods
CN102558334B (zh) * 2004-09-07 2016-08-03 伯纳姆研究院 选择性锚定到心脏脉管系统上的肽和相关结合物和方法
EP1853289A4 (fr) * 2005-01-31 2008-04-09 Vaxinnate Corp Nouveaux ligands de polypeptides destines a un recepteur de type toll 2 (tlr2)
CA2603140A1 (fr) * 2005-03-22 2006-09-28 Novozymes A/S Utilisation de polypeptides bacillus licheniformis dans les aliments pour animaux
EP1907534B2 (fr) * 2005-07-12 2024-04-10 Micreos B.V. Bacteriophage et utilisations
US7592009B2 (en) * 2006-10-10 2009-09-22 Ecole Polytechnique Federale De Lausanne (Epfl) Polypeptide ligands for targeting cartilage and methods of use thereof
DE602006012515D1 (de) * 2006-12-15 2010-04-08 Giuseppe Campiani Neuartige mit Taxan verwandte Peptide und deren Verwendung
CA2715396A1 (fr) * 2008-02-19 2009-08-27 James J. Hogan Compositions et procedes pour la detection d'acide nucleique de propionibacterium acnes
WO2009120993A2 (fr) * 2008-03-28 2009-10-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Analogues synthétiques du domaine juxtamembranaire de l'igf1r et leurs utilisations
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
US9340769B2 (en) * 2008-12-05 2016-05-17 The Regents Of The University Of California Methods and compositions for treating P. acnes
CN104127879B (zh) 2008-12-05 2017-05-10 阿布拉西斯生物科学有限责任公司 结合SPARC的scFv
FR2945125B1 (fr) * 2009-05-04 2013-07-19 Ingen Biosciences Methode de diagnostic des infections a propionibacterium acnes
PL2248533T3 (pl) * 2009-05-05 2014-04-30 Univ Freiburg Polipeptyd pochodzący od enterokoka i jego zastosowanie do szczepienia
FR2959229B1 (fr) * 2010-04-21 2013-01-18 Vect Horus Derives peptidiques, leur preparation et leurs utilisations
SG185487A1 (en) * 2010-05-11 2012-12-28 Aveo Pharmaceuticals Inc Anti-fgfr2 antibodies
AU2011259204B2 (en) 2010-05-27 2015-05-21 Kenichiro Hasumi Antigen peptide and use thereof
EP3692999A1 (fr) 2012-03-17 2020-08-12 The Regents of the University of California Diagnostic et traitements personnalisés rapides de l'acné
US10295547B2 (en) * 2013-03-14 2019-05-21 University Of Florida Research Foundation, Incorporated Use and treatment of di-amino acid repeat-containing proteins associated with ALS
WO2015138494A1 (fr) 2014-03-10 2015-09-17 Georges Belfort Peptides anti-microbiens et procédé de conception de nouveaux peptides anti-microbiens
CN106661543A (zh) 2014-06-17 2017-05-10 Xycrobe治疗公司 经遗传修饰的细菌和用于细菌的遗传修饰的方法
PL3356390T3 (pl) 2015-09-28 2021-07-05 The University Of North Carolina At Chapel Hill Sposoby i kompozycje dla wektorów wirusowych unikających przeciwciał
WO2017141248A1 (fr) * 2016-02-17 2017-08-24 Pepticom Ltd Agonistes et antagonistes peptidiques de l'activation de tlr4
US11504404B2 (en) 2016-02-24 2022-11-22 Crown Laboratories, Inc. Skin probiotic formulation
JP2019514885A (ja) 2016-04-21 2019-06-06 ネイキッド バイオーム，インク． 皮膚障害の処置のための組成物および方法
CN106167820A (zh) * 2016-05-19 2016-11-30 胤安国际（辽宁）基因科技股份有限公司 鉴定或辅助鉴定痤疮丙酸杆菌的专用引物及其应用
JP7350337B2 (ja) 2017-09-26 2023-09-26 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 神経障害の処置においてｒａｎタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用
US12091435B2 (en) 2018-04-03 2024-09-17 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
JP7406677B2 (ja) 2018-04-03 2023-12-28 ギンコ バイオワークス インコーポレイテッド 抗体を回避するウイルスベクター
US20210401976A1 (en) * 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
JP2022507968A (ja) * 2018-11-26 2022-01-18 ノース カロライナ ステイト ユニヴァーシティ 宿主細胞タンパク質の捕捉のためのペプチドリガンド
JP7378839B2 (ja) * 2018-12-26 2023-11-14 スキンメドカンパニーリミテッド アセチルコリン受容体阻害ペプチド及びその用途
WO2020191300A1 (fr) 2019-03-21 2020-09-24 Stridebio, Inc. Vecteurs viraux adéno-associés recombinants
TW202128736A (zh) 2019-10-17 2021-08-01 美商史崔德生物公司 用於治療ｃ型尼曼—匹克病之腺相關病毒載體
US20230048338A1 (en) * 2019-12-20 2023-02-16 PYC Therapeutics Limited Novel cellular delivery methods
KR20230005127A (ko) 2020-02-21 2023-01-09 오리짐 바이오테크놀로지 게엠베하 프로피오니박테리움 아크네스 예방적 및 치료적 면역 처치
WO2021231988A2 (fr) * 2020-05-15 2021-11-18 University Of Southern California Peptides dérivés de mitochondries et leurs analogues destinés à être utilisés en tant que thérapie pour des maladies liées à l'âge y compris le cancer
EP4167937A1 (fr) 2020-06-23 2023-04-26 Crown Laboratories, Inc. Formulations cutanées probiotiques
AR123288A1 (es) 2020-08-19 2022-11-16 Stridebio Inc Vectores de virus adenoasociados para el tratamiento del síndrome de rett
KR20230083100A (ko) * 2021-12-02 2023-06-09 삼성전자주식회사 폴리펩티드, 이를 포함하는 포토레지스트 조성물 및 이를 이용한 패턴 형성 방법
WO2024145574A2 (fr) * 2022-12-30 2024-07-04 Cedars-Sinai Medical Center Vaccins ciblant la hyaluronidase c. acnes pour la prophylaxie et le traitement de l'acné vulgaire

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CORIXA CORPORATION - POWERING THE IMMUNE SYSTEM, XP002180961, Retrieved from the Internet <URL:http://www.corixa.com/default.asp?pid=release_detail&year=2001&ID=9> [retrieved on 20011018] *
DATABASE EMBL 16 February 1998 (1998-02-16), NATIONAL CANCER INSTITUTE: "nj43f09.s1 NCI_CGAP_Pr9 Homo sapiens cDNA clone", XP002281294, accession no. ACCESSION NUMBER AA809595 *
MISKIN J E ET AL: "PROPIONIBACTERIUM ACNES, A RESIDENT OF LIPID-RICH HUMAN SKIN, PRODUCES A 33 KDA EXTRACELLULAR LIPASE ENCODED BY GEHA", MICROBIOLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 143, no. 5, 1997, pages 1745 - 1755, XP000952640, ISSN: 1350-0872 *
STEINER B ET AL: "CLONING AND SEQUENCING OF THE HYALURONATE LYASE GENE FROM PROPIONIBACTERIUM ACNES", CANADIAN JOURNAL OF MICROBIOLOGY, OTTAWA, CA, vol. 43, no. 4, 1997, pages 315 - 321, XP000952641, ISSN: 0008-4166 *

Also Published As

Publication number Publication date
AU2001255524A1 (en) 2001-11-07
EP1278854A2 (fr) 2003-01-29
CA2407352A1 (fr) 2001-11-01
JP2004520803A (ja) 2004-07-15
WO2001081581A9 (fr) 2003-01-03
WO2001081581A2 (fr) 2001-11-01

Similar Documents

Publication Publication Date Title
WO2001081581A3 (fr) Compositions et procedes pour la therapie et le diagnostic de l&#39;acne vulgaire
WO2001092581A8 (fr) Compositions et methodes permettant le traitement et le diagnostic du cancer de l&#39;ovaire
WO2001072295A3 (fr) Compositions et methodes pouvant traiter ou diagnostiquer le cancer du poumon
WO2001096388A8 (fr) Compositions et procedes servant a traiter et a diagnostiquer le cancer du colon
WO2001000828A3 (fr) Compositions et techniques de therapie et de diagnostic du cancer du poumon
WO2002060317A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du pancreas
WO2001096390A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du colon
WO2001034802A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer de la prostate
WO2000004149A3 (fr) Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2000060077A3 (fr) Composes utilises dans la therapie et le diagnostic du cancer du poumon et methodes d&#39;utilisation
WO2001051633A3 (fr) Compositions et methodes destinees au traitement et au diagnostique du cancer de la prostate
WO2001073032A3 (fr) Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2002004514A3 (fr) Compositions et procedes pour le traitement et le diagnostic du cancer du poumon
WO2001079286A3 (fr) Compositions et procedes de traitement et de diagnostic du cancer du sein
WO2002074237A8 (fr) Compositions et procedes de therapie et de diagnostic du cancer du rein
WO2002092001A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer du poumon
WO2000037643A3 (fr) Composes destines a l&#39;immunotherapie et au diagnostic du cancer du colon et methodes d&#39;utilisation
WO2002012328A8 (fr) Compositions et methodes utilisees dans la therapie et le diagnostic du cancer du colon
WO2003037267A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer des poumons
WO2002058534A8 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du colon
WO2001077168A3 (fr) Compositions et procedes permettant de traiter et de diagnostiquer le cancer du poumon
WO2002039885A3 (fr) Compositions et methodes destinees a la therapie et au diagnostic du cancer de l&#39;ovaire
WO2001057207A3 (fr) Compositions et methodes destinees a la therapie et au diagnostic du cancer de l&#39;ovaire
WO2002012280A3 (fr) Compositions et procedes pour le diagnostic et le traitement du cancer du colon
WO2001090152A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du sein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 578652

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2407352

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001928693

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: TABLE 2, DESCRIPTION, ADDED (10 PAGES)

WWP Wipo information: published in national office

Ref document number: 2001928693

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWW Wipo information: withdrawn in national office

Ref document number: 2001928693

Country of ref document: EP